BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

DELIVERY ORDER won by THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · work in HOUSTON, TX
$843,496
RecipientTHE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER UEI S3GMKS8ELA16
Award ID75N91020F00001
Award amount$843,496
Award typeDELIVERY ORDER
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSCAN12
Start dateJun 1, 2020
End dateNov 30, 2022
Place of performanceHOUSTON, TX
Record updatedAug 30, 2022

View the official award record

Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.

Search open bids